|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00528619 |
Purpose
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
| Condition | Intervention | Phase |
|
Non-Small Cell Lung Cancer Mesothelioma Neoplasms |
Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin |
Phase I |
| MedlinePlus related topics: | Cancer Lung Cancer Mesothelioma |
| Drug Information available for: | Carboplatin Cisplatin Sunitinib Sunitinib malate Pemetrexed disodium Pemetrexed |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Phase I Study Of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin And Pemetrexed/Carboplatin In Patients With Advanced Solid Malignancies |
| Estimated Enrollment: | 100 |
| Study Start Date: | November 2006 |
| Estimated Study Completion Date: | May 2009 |
| Arms | Assigned Interventions |
| A: Experimental |
Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
|
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Pfizer Oncology Clinical Trial Information Service | 1-877-369-9753 | PfizerCancerTrials@emergingmed.com |
| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
| United States, Colorado | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Aurora, Colorado, United States, 80012 | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Aurora, Colorado, United States, 80045 | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Denver, Colorado, United States, 80218 | |||||
| Canada, Ontario | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Ottawa, Ontario, Canada, K1H 8L6 | |||||
| Canada, Quebec | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Montreal, Quebec, Canada, H2L 4M1 | |||||
| Pfizer |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
To obtain contact information for a study center near you, click here. 
  |
| Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
| Study ID Numbers: | A6181084 |
| First Received: | September 10, 2007 |
| Last Updated: | November 1, 2008 |
| ClinicalTrials.gov Identifier: | NCT00528619 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|